TICKERNERD
Menu
GANXGANXHealthcare · Biotechnology

GANX Stock Forecast: Gain Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$1.13
−5.04% on the day

The 5 Wall Street analysts covering Gain Therapeutics, Inc. hold a median 12-month price target of $8 — +608.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 27 of 100 as at 31 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$49.3M
Ticker Nerd rank
27/ 100
Median analyst target
$8.00
Analysts covering
5
Revenue$0.0
Operating income−$4.7M
Net income−$4.7M
Free cash flow−$4.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−10.3%
1M
−34.7%
YTD
−64.9%
1Y
−35.8%
From 52W high
−73.0%
From 52W low
0.0%
$1.13
$4.18
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

GANX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Gain Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
27/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
80
Revisions
56
Momentum
46
Issuance
39
Accruals
34
Value
34
Growth
31
Volatility
20
Quality
16

Size (80): Smaller than most of the companies we track.

Quality (16): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

GANX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GANX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00Jan 26Apr 26Jul 26Oct 26GANXHigh $8.00Median $8.00Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $5.00Median $8.00High $8.00

The green dot is the last close — the median target sits +608.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
5 Oct 2026HC Wainwright & Co.ReiteratesBuy$8.00
31 Aug 2026HC Wainwright & Co.ReiteratesBuy—
31 Aug 2026HC Wainwright & Co.ReiteratesBuy$8.00
11 Aug 2026BTIGReiteratesBuy$5.00
11 Aug 2026BTIGReiteratesBuy—
1 July 2026HC Wainwright & Co.ReiteratesBuy$8.00
1 July 2026HC Wainwright & Co.ReiteratesBuy—
30 June 2026BTIGMaintainsBuy$5.00
30 June 2026BTIGMaintainsBuy—
19 Dec 2025HC Wainwright & Co.ReiteratesBuy—
15 Oct 2025BTIGReiteratesBuy—
13 Oct 2025HC Wainwright & Co.ReiteratesBuy—
7 Oct 2025Maxim GroupMaintainsBuy—
8 Sept 2025BTIGReiteratesBuy—
13 Aug 2025Roth CapitalMaintainsBuy—
3 July 2025HC Wainwright & Co.ReiteratesBuy—
19 May 2025HC Wainwright & Co.ReiteratesBuy—
28 Mar 2025Chardan CapitalMaintainsBuy—
17 Mar 2025HC Wainwright & Co.ReiteratesBuy—
7 Mar 2025ScotiabankInitiatesSector Outperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

GANX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

GANX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, Gain Therapeutics, Inc. returned −35.8% against +12.4% for the S&P 500, dividends included.

GANX vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200250Jan 26Apr 26Jul 26Oct 26GANXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

GANX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Gain Therapeutics, Inc. (GANX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.9×

Cheaper than 86% of US stocks

Price / sales
—
Price / book
4.3×

Cheaper than 22% of US stocks

EV / EBITDA
−1.9×

Cheaper than 73% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−268.3%

Higher than 6% of US stocks

Return on assets
−95.5%

Higher than 3% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Gain Therapeutics, Inc. (GANX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Gain Therapeutics, Inc. has a market value of $49.3M and an enterprise value of $36.8M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$20.1M.

  • Free cash flow in the twelve months to 30 June 2026: −$19.0M.

  • Shares outstanding: 42.7M.

  • Trailing P/E: −1.9×; forward P/E: −1.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Gain Therapeutics, Inc. employs 20 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 1 Nov 2026

Data provided by Twelve Data

Peers

GANX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
GANXGain Therapeutics, Inc.$49.3M27
HOWLWerewolf Therapeutics, Inc.$47.9M87
ANVSAnnovis Bio, Inc.$48.1M27
IMAImageneBio, Inc.$48.4M28
IBIOiBio, Inc.$46.8M22
HYPDHyperion DeFi, Inc.$48.8M42
ATNMActinium Pharmaceuticals, Inc.$46.4M80

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Gain Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest GANX news & analysis

Sibylla Biotech Appoints Usman Azam CEO, Gianluca Fuggetta CFO, and Expands Executive Team to Drive Transition to Clinic

GlobeNewsWire · 13 Oct 2026neutral

Sibylla Biotech appointed Usman Azam as CEO and Gianluca Fuggetta as CFO, and promoted Elena Ardini to Chief Scientific Officer. Co-founder and former CEO Lidia Pieri will remain as COO as the company prepares to move its lead program toward clinical evaluation.

Why it matters — GANX watchers may note Sibylla’s executive expansion and stated progress toward clinical evaluation of its lead program, though the excerpt does not describe a direct connection to Gain Therapeutics.

Gain Therapeutics to Attend the 2026 Maxim Growth Summit

GlobeNewsWire · 8 Oct 2026neutral

Gain Therapeutics announced that it will participate in the 2026 Maxim Growth Summit, scheduled for October 12–14 at The Hard Rock Hotel New York in New York City.

Why it matters — GANX watchers may note the company’s planned participation in an upcoming investor-focused summit.

Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration

GlobeNewsWire · 1 Oct 2026positive

Gain Therapeutics presented positive Phase 1b open-label extension data for rexaceract, showing further evidence of disease-modifying activity through 12 months of administration. Among the 12 evaluable participants who completed 12 months of daily oral dosing by August 31, 2026, MDS-UPDRS motor scores demonstrated stability to baseline with no disease progression.

Why it matters — GANX watchers would care because the data provide additional evidence supporting rexaceract's potential disease-modifying activity, a key milestone for the company's lead Parkinson's disease candidate.

Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson's Disease and Movement Disorders

GlobeNewsWire · 29 Sept 2026positive

Gain Therapeutics announced a poster presentation at the International Congress of Parkinson's Disease and Movement Disorders, to be held October 4-8, 2026, in Seoul, Korea. The company described itself as a clinical-stage biotechnology firm focused on developing the next generation of allosteric small molecule therapies.

Why it matters — A poster presentation at a major international Parkinson's conference signals research visibility and potential scientific engagement for GANX in its therapeutic area.

Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference

GlobeNewsWire · 17 Sept 2026neutral

Gain Therapeutics announced that President and CEO Gene Mack will participate in an industry panel and one-on-one meetings at the ROTH Fifth Annual Healthcare Opportunities Conference, to be held September 29 at the Metropolitan Club in New York. The company is a clinical-stage biotechnology firm focused on allosteric small molecule therapies.

Why it matters — The CEO's participation and investor meetings at a healthcare conference could raise Gain Therapeutics' visibility with investors and the broader biotech community.

FAQ

Frequently asked questions about GANX stock

What is the GANX stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Gain Therapeutics, Inc. have a median 12-month price target of $8, with estimates ranging from $5 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is GANX stock a buy right now?

Of the 5 analysts covering Gain Therapeutics, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Gain Therapeutics, Inc. 27 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GANX?

As at 31 Oct 2026, Gain Therapeutics, Inc. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (80 of 100).

Will GANX stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +608.0% from the last close, and Ticker Nerd's factor model ranks Gain Therapeutics, Inc. 27 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the GANX stock forecast for 2030?

No analyst covering Gain Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GANX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $8 over the next 12 months.

How has GANX stock performed over the past year?

Gain Therapeutics, Inc. returned -35.8% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Gain Therapeutics, Inc. do?

Gain Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing allosteric small molecule therapies for difficult-to-treat diseases.

What is the latest news on GANX?

The most recent item we track (GlobeNewsWire, 13 Oct 2026): "Sibylla Biotech Appoints Usman Azam CEO, Gianluca Fuggetta CFO, and Expands Executive Team to Drive Transition to Clinic". Sibylla Biotech appointed Usman Azam as CEO and Gianluca Fuggetta as CFO, and promoted Elena Ardini to Chief Scientific Officer. Co-founder and former CEO Lidia Pieri will remain as COO as the company prepares to move its lead program toward clinical evaluation.

Company

About Gain Therapeutics, Inc.

Gain Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing allosteric small molecule therapies for difficult-to-treat diseases. Its current research centers on neurodegenerative disorders and other conditions linked to protein misfolding, with a particular emphasis on Parkinson’s disease and select rare genetic diseases. The company’s lead candidate, GT-02287, is being evaluated for Parkinson’s disease and is part of a broader pipeline aimed at addressing underlying disease mechanisms rather than only managing symptoms. Gain Therapeutics also uses its Magellan drug discovery platform to identify novel allosteric binding sites and design proprietary compounds with the potential to modulate protein function. Headquartered in Bethesda, Maryland, Gain Therapeutics operates as a specialized player in precision medicine and computational drug discovery within the biotechnology sector.

CEO Mr. Gene Mack M.B.A. · 20 employees · United States · https://gaintherapeutics.com